95215-50-2

Basic information

• Product Name: 4(1H)-Pyridinone, 1-(2-hydroxyethyl)-2-methyl-3-(phenylmethoxy)-
• CAS NO: 95215-50-2
• Molecular Formula: C15H17NO3
• Molecular Weight: 259.305
• Mol File: 95215-50-2.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 4(1H)-Pyridinone, 1-(2-hydroxyethyl)-2-methyl-3-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyridinone, 1-(2-hydroxyethyl)-2-methyl-3-(phenylmethoxy)-(95215-50-2)
• EPA Substance Registry System: 4(1H)-Pyridinone, 1-(2-hydroxyethyl)-2-methyl-3-(phenylmethoxy)-(95215-50-2)

Safety Data

• Hazardous Substances Data: 95215-50-2(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 95215-49-9 1-acetyl-3-hydroxy-2-methylpyrid-4-one 
• 61049-69-2 3-O-benzylmaltol 
• 141-43-5 ethanolamine 
• 118-71-8 Maltol 

Downstream Products

• 874383-28-5 1-[2'-(diethylphosphonomethoxy)ethyl]-2-methyl-3-benzyloxy-4-pyridinone 
• 30652-21-2 CP40 
• 1219111-68-8 3-(benzyloxy)-1-(2-(benzyloxy)ethyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid 
• 1219111-74-6 3-(benzyloxy)-1-(2-(benzyloxy)ethyl)-4-oxo-1,4-dihydropyridine-2-carbaldehyde 
• 1219111-72-4 3-(benzyloxy)-1-(2-(benzyloxy)ethyl)-2-methylpyridin-4(1H)-one 
• 773835-48-6 1-[2'-(benzoyloxy)ethyl]-2-methyl-3-hydroxy-4(1H)-pyridinone 

Relevant articles and documents

Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy

The blood–brain barrier (BBB) permeability of molecules needs to meet stringent requirements of Lipinski’s rule, which pose a difficulty for the rational design of efficient chelating agents for Parkinson's disease chelation therapy. Therefore, the iron c

CN128: A New Orally Active Hydroxypyridinone Iron Chelator

Deferoxamine, deferiprone, and deferasirox are used for the treatment of systemic iron overload, although they possess limitations due to lack of oral activity, lower efficacy, and side effects. These limitations led to a search for an orally active iron chelator with an improved therapeutic index. The lower efficacy of deferiprone is due to rapid glucuronidation, leading to the formation of a nonchelating metabolite. Here, we demonstrate that the influence of metabolism can be reduced by introducing a sacrificial site for glucuronidation. A log P-guided investigation of 20 hydroxpyridinones led to the identification of CN128. The Fe(III) affinity and metal selectivity of CN128 are similar to those of deferiprone, the log P value is more lipophilic, and its iron scavenging ability is superior. Overall, CN128 was demonstrated to be safe in a range of toxicity assessments and is now in clinical trials for the treatment of β-thalassemia after regular blood transfusion.

Novel 3-hydroxypyridin-4-one hexadentate ligand-based polymeric iron chelator: Synthesis, characterization and antimicrobial evaluation

A novel 3-hydroxypyridin-4-one (HPO) hexadentate monomeric chelator 14 has been synthesized and incorporated into polymers by copolymerization with 2-hydroxyethyl acrylate (HEA), using azobisisobutyronitrile (AIBN) as an initiator. The monomeric chelator was found to possess very high affinity for iron(III), with the log stability constant of the iron complex (log K1) = 33.61 and pFe3+ = 30.37. The iron binding capacity and monomer recovery of the copolymers were determined using spectrophotometry. The in vitro antimicrobial activity of monomeric chelator 14 and polymeric chelator 16-4 against both Gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis) and Gram-negative bacteria (Escherichia coli, Salmonella spp., and Pseudomonas aeruginosa) was evaluated by inhibition zone and minimum inhibitory concentration (MIC) assays, which demonstrated that both monomeric and polymeric chelators possess inhibitory activity. The polymeric chelators possess potential application for the treatment of wound infection.